Hyperlipidemic heart transplant patients who develop cardiac allograft vasculopathy (CAV) benefit from HELP-apheresis (Heparin-induced Extracorporeal LDL Precipitation) which enables drastic lowering of plasma low-density lipoprotein, lipoprotein (a), and fibrinogen. There is evidence that HELP-apheresis also improves microcirculation by an immediate improvement of impaired endothelial-dependent vasodilatation and additive hemorheological effects.Therefore, cutaneous microcirculation was examined before, during, and after the first HELP-apheresis in eight hyperlipidemic cardiac transplant recipients with CAV. To study the long-term effect the intravital microscopy was repeated after three and 12 months of weekly apheresis treatment.In CAV patients the baseline mean erythrocyte velocity was pathologically reduced with 0.13±0.07 mm/s. During the first HELP-apheresis the erythrocyte velocity increased significantly (p = 0.0001) and remained increased until the end of the HELP procedure (p < 0.05). After three months of weekly apheresis treatment a decrease of temporary flow stops in the capillaries with a progressive homogenization (concordance) of the cutaneous microcirculation was observed. After one year of weekly treatment a markedly increase in mean erythrocyte velocity under resting conditions occurred. In addition, a reactive post-ischemic hyperemia could be established for the first time.Even the first single HELP-apheresis resulted in a significant improvement of the cutaneous microcirculation. The long-term treatment of these patients resulted in a marked improvement of the cutaneous microcirculation with the tendency to a normalization of the regulation of the capillary perfusion.

Download full-text PDF

Source
http://dx.doi.org/10.3233/CH-199216DOI Listing

Publication Analysis

Top Keywords

extracorporeal ldl
8
cardiac allograft
8
allograft vasculopathy
8
erythrocyte velocity
8
help-heparin-induced extracorporeal
4
ldl precipitation-apheresis
4
precipitation-apheresis heart
4
heart recipients
4
recipients cardiac
4
vasculopathy concomitant
4

Similar Publications

Arterial hypertension and increased atherogenic index of plasma (AIP) are strong predictors of cardiovascular risk associated in individuals with obesity both in adults and children. Thus, we aimed to explore the relationship between AIP and systolic ambulatory blood pressure index (sABPI) with left ventricular geometry pattern in obese children. In this cross-sectional study, a total of 129 obese children (BMI greater or equal to the 95th percentile for age and sex) were examined.

View Article and Find Full Text PDF

Management of a young HoFH patient during pregnancy using Lipoprotein Apheresis (whole blood): A novel experience.

Transfus Apher Sci

December 2024

Department of Maternal and Child Health and Urological Sciences, Umberto I Hospital, "Sapienza" University of Rome, Viale del Policlinico 155, Rome 00161, Italy. Electronic address:

The pregnancy of a patient with homozygous familial hypercholesterolemia (HoFH) represents a challenge in the clinical setting due to the high cardiovascular risk of the mother and maternal-fetal morbidity. The lipid lowering drugs are generally contraindicated and lipoprotein apheresis (LA) is the only accepted treatment in HoFH pregnant woman. Liposorber D, an LA technique on whole blood, has good efficacy, safety, and short operative time.

View Article and Find Full Text PDF

Causal effects of lipid-lowering drugs on skin diseases: a two-sample Mendelian randomization study.

Front Med (Lausanne)

September 2024

Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Department of Dermatology and STD, The Third Central Hospital of Tianjin, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin, China.

Article Synopsis
  • The study explores the causal relationship between lipid-lowering drugs and skin conditions, focusing on LDL's potential role in skin cancers and psoriasis.
  • Using advanced statistical methods like Mendelian randomization, researchers analyzed genetic data to assess the effects of two specific drugs: HMGCR inhibitors (like statins) and PCSK9 inhibitors (like alirocumab).
  • Results indicate that HMGCR inhibitors are linked to a lower risk of nonmelanoma skin cancer and psoriasis, while PCSK9 inhibitors also show promise in reducing psoriasis risk among Europeans.
View Article and Find Full Text PDF

Retinopathy, small fiber neuropathy (SFN), and encephalopathy associated with recoverin antibodies have not been previously reported as side effects of BNT162b2 vaccination in a patient with HLA-B27-associated spondylarthritis. The patient is a 47-year-old male with a 10-year history of HLA-B27-associated spondylarthritis without recurrence, who developed acute and post-acute COVID vaccination syndrome (ACVS/PACVS) after the first dose of the BNT162b2 vaccine. The PACVS manifested as cerebral disease, eye disease, and SFN.

View Article and Find Full Text PDF

Background And Aims: Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder characterized by severely elevated LDL cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. In the pivotal Phase 3 HoFH trial (NCT03399786), evinacumab significantly decreased LDL-C in patients with HoFH. This study assesses the long-term safety and efficacy of evinacumab in adult and adolescent patients with HoFH.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!